1. Generics Bulletin
  2. >>Business
  3. >>Deals

Strides Grows In Central Europe Through Fairmed Deal

 
• By Penelope MacRae

Strides Pharma Science has acquired a majority stake in Swiss generics firm Fairmed Healthcare in a move to bolster its presence in central Europe. The acquisition marks the latest in a string of transactions by the Indian firm.

70_Per_Cent
Strides Acquires A 70% Stake In Fairmed Healthcare • Source: Shutterstock

Strides has acquired a majority stake in Swiss generics company Fairmed Healthcare in a move that will ramp up its fast-expanding “other regulated markets business” and provide the Indian drugmaker with a strong foothold in continental Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By Adam Zamecnik

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

More from Business